Epirubicin

UC

Diwakar DavarPhase 2Active

B

60/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 45/ 100
Competitive Position: 95/ 100

Competitive context

2 Active assets in the UC cohort.

Asset / Sponsor	Phase	Rating
Cyclophosphamide Diwakar Davar	Phase 2	B
Pembrolizumab Diwakar Davar	Phase 2	B
TRASTUZUMAB Incyte Corporation	Phase 1/2	CC
Docetaxel Incyte Corporation	Phase 1/2	CC
Pemigatinib Incyte Corporation	Phase 1/2	CC
CIS-DIAMMINEDICHLOROPLATINUM II Incyte Corporation	Phase 1/2	CC
Retifanlimab Incyte Corporation	Phase 1/2	CC

Same molecule, other indications

Epirubicin is also rated in:

Recurrent Breast CarcinomaDormant

BBB

Indicative ·

74 / 100

Lung Non-Small Cell Squamous CarcinomaDormant

BBB

Indicative ·

72 / 100

Advanced/Metastatic Gastroesophageal AdenocarcinomaDormant

BBB

Indicative ·

72 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.